Mounjaro Weight-Loss Jab Shortage: What Patients Need to Know

Step 1, understand why the Mounjaro jab shortage happened

Tirzepatide was approved for weight management in the UK in November 2023, and take-up exceeded Eli Lilly's early production forecasts. Weight-loss medicines require complex biological manufacturing processes that cannot be scaled quickly: specialist fermentation equipment, extended quality-testing timelines, and multi-site supply chains all create lead times measured in months, not weeks. The result has been a structural gap between what patients need and what wholesalers can dispatch at any given time.

Demand has grown sharply as awareness of the medicine has risen, and as the NHS began rolling out tirzepatide through primary care from 2025 onwards, adding NHS patients to the same supply pipeline that private pharmacies draw on. The tirzepatide overview on this site explains the medicine's mechanism and licensed indications in more detail if you are still deciding whether it is right for you.

Shortages have not been uniform. The 2.5mg starter dose has generally remained more available, because patients cycle through it in their first month and move on. Doses above 7.5mg have been the most consistently tight. Some periods have seen specific pen batches held at customs or delayed by logistics rather than outright absent from the manufacturer. The picture changes week by week.

Step 2, check what the shortage means for your current treatment

If you are already on Mounjaro and your usual pharmacy cannot supply your current dose, the first call to make is to your prescriber, not to a search engine. Abruptly stopping treatment part-way through a course is not advisable without clinical input: your prescriber can consider whether stepping back temporarily to a lower available dose, extending your interval under supervision, or pausing treatment is the right approach for your circumstances.

The NHS England guidance on weight-management injections notes that patient safety is the priority during supply disruption and that decisions about dose changes should be made clinically, not by patients acting alone. Do not attempt to split pens, adjust your own injection volume, or source a different strength informally to bridge a gap, these approaches create dosing risks that outweigh the inconvenience of a short pause.

If you are considering switching provider during a shortage, check whether the new pharmacy is registered with the GPhC before sharing any personal or medical information. You can verify any pharmacy's registration quickly at the GPhC register.

Step 3, know which sources to trust (and which to avoid)

Shortages create a market for counterfeits. The MHRA has been clear on this: fake tirzepatide pens have been seized in the UK, and if you want to understand the background to why the tirzepatide shortage has made counterfeit products more prevalent, our dedicated page covers the supply factors in detail, including an illicit manufacturing site in Northampton in October 2025, with approximately 20 million doses of illegally traded weight-loss medicines (worth around £45 million) recovered during 2025 enforcement operations. Counterfeit pens have previously been found to contain insulin or other substances, a potentially life-threatening substitution.

Red flags to recognise: a seller offering Mounjaro without asking for a prescription or completing any clinical assessment; prices that sit well below anything a registered pharmacy quotes; sellers operating only through social media direct messages or unofficial websites. The MHRA's Yellow Card scheme lets you report a suspected fake product or seller, that report genuinely helps enforcement teams track supply chains.

For context on how private prices have moved during the shortage period, including the Eli Lilly list-price increase that took effect from September 2025, the Mounjaro cost comparison page sets out what legitimate providers typically charge and what those figures include. A low headline price is not a saving if the medicine in the pen is not what it claims to be.

Step 4, know the current supply picture and where to get accurate updates

Supply availability shifts frequently enough that any specific forecast risks being out of date within days. If you want a dedicated breakdown of the factors driving availability week to week, our page on the Mounjaro shortage in the UK covers the history and current state in one place. The most reliable sources for the current picture are also the MHRA's medicines shortage communications and Eli Lilly UK's supply updates, both published on official channels. Your prescriber or pharmacist can also check real-time wholesaler stock.

At nume, our prescribers review supply at the point of each consultation, so patients are not told they have been approved for a dose that is not actually available for dispatch. If a particular strength is constrained when you consult, our clinical team will discuss options with you directly. You can read more about whether the Mounjaro shortage is ongoing or look at the broader UK shortage picture for a fuller breakdown by dose and region.

If you are ready to find out whether treatment is clinically suitable for you and whether stock is currently available at the dose relevant to your stage, speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered clinician, with no algorithm involved.